579 related articles for article (PubMed ID: 32871689)
1. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
McIntyre RS; Carvalho IP; Lui LMW; Majeed A; Masand PS; Gill H; Rodrigues NB; Lipsitz O; Coles AC; Lee Y; Tamura JK; Iacobucci M; Phan L; Nasri F; Singhal N; Wong ER; Subramaniapillai M; Mansur R; Ho R; Lam RW; Rosenblat JD
J Affect Disord; 2020 Nov; 276():576-584. PubMed ID: 32871689
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
Seshadri A; Prokop LJ; Singh B
J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.
Terao I; Tsuge T; Endo K; Kodama W
J Affect Disord; 2024 Feb; 346():49-56. PubMed ID: 37949235
[TBL] [Abstract][Full Text] [Related]
4. Esketamine: A Novel Option for Treatment-Resistant Depression.
Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
[No Abstract] [Full Text] [Related]
5. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Xiong J; Lipsitz O; Chen-Li D; Rosenblat JD; Rodrigues NB; Carvalho I; Lui LMW; Gill H; Narsi F; Mansur RB; Lee Y; McIntyre RS
J Psychiatr Res; 2021 Feb; 134():57-68. PubMed ID: 33360864
[TBL] [Abstract][Full Text] [Related]
6. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Kryst J; Kawalec P; Pilc A
Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
[No Abstract] [Full Text] [Related]
8. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; van Asselt ADI; Touw DJ; Aan Het Rot M; Schoevers RA
BMC Psychiatry; 2019 Nov; 19(1):375. PubMed ID: 31783823
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review.
Ng J; Rosenblat JD; Lui LMW; Teopiz KM; Lee Y; Lipsitz O; Mansur RB; Rodrigues NB; Nasri F; Gill H; Cha DS; Subramaniapillai M; Ho RC; Cao B; McIntyre RS
J Affect Disord; 2021 Oct; 293():285-294. PubMed ID: 34225208
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
Papakostas GI; Salloum NC; Hock RS; Jha MK; Murrough JW; Mathew SJ; Iosifescu DV; Fava M
J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459407
[TBL] [Abstract][Full Text] [Related]
12. Compounded intranasal racemic ketamine for major depressive disorder: A case report.
Ziegler L; Peters E; Wanson A; Halpape K
Exp Clin Psychopharmacol; 2021 Dec; 29(6):750-754. PubMed ID: 33661659
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL
J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113
[No Abstract] [Full Text] [Related]
15. Intranasal esketamine: From origins to future implications in treatment-resistant depression.
Sanders B; Brula AQ
J Psychiatr Res; 2021 May; 137():29-35. PubMed ID: 33647726
[TBL] [Abstract][Full Text] [Related]
16. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
Kritzer MD; Mischel NA; Young JR; Lai CS; Masand PS; Szabo ST; Mathew SJ
Ann Clin Psychiatry; 2022 Feb; 34(1):33-43. PubMed ID: 35166663
[TBL] [Abstract][Full Text] [Related]
17. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
Banov MD; Landrum RE; Moore MB; Szabo ST
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
[TBL] [Abstract][Full Text] [Related]
18. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
[TBL] [Abstract][Full Text] [Related]
19. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
[TBL] [Abstract][Full Text] [Related]
20. The antidepressant effect and safety of non-intranasal esketamine: A systematic review.
Smith-Apeldoorn SY; Vischjager M; Veraart JK; Kamphuis J; Aan Het Rot M; Schoevers RA
J Psychopharmacol; 2022 May; 36(5):531-544. PubMed ID: 35546042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
